NO20063842L - Silinanforbindelser som cysteinproteaseinhibitorer - Google Patents
Silinanforbindelser som cysteinproteaseinhibitorerInfo
- Publication number
- NO20063842L NO20063842L NO20063842A NO20063842A NO20063842L NO 20063842 L NO20063842 L NO 20063842L NO 20063842 A NO20063842 A NO 20063842A NO 20063842 A NO20063842 A NO 20063842A NO 20063842 L NO20063842 L NO 20063842L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- silinan
- protease inhibitors
- cysteine protease
- relates
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000002852 cysteine proteinase inhibitor Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 102000005600 Cathepsins Human genes 0.000 abstract 1
- 108010084457 Cathepsins Proteins 0.000 abstract 1
- 102000005927 Cysteine Proteases Human genes 0.000 abstract 1
- 108010005843 Cysteine Proteases Proteins 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 230000002939 deleterious effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54058104P | 2004-01-30 | 2004-01-30 | |
| US54749804P | 2004-02-24 | 2004-02-24 | |
| PCT/US2005/002773 WO2005074904A2 (en) | 2004-01-30 | 2005-01-31 | Silinane compounds as cysteine protease inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20063842L true NO20063842L (no) | 2006-10-20 |
Family
ID=34841106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20063842A NO20063842L (no) | 2004-01-30 | 2006-08-29 | Silinanforbindelser som cysteinproteaseinhibitorer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20070088001A1 (pt) |
| EP (1) | EP1716158A2 (pt) |
| JP (1) | JP2007519744A (pt) |
| KR (1) | KR20060129416A (pt) |
| AU (1) | AU2005210631A1 (pt) |
| BR (1) | BRPI0506494A (pt) |
| CA (1) | CA2554626A1 (pt) |
| CR (1) | CR8574A (pt) |
| EC (1) | ECSP066805A (pt) |
| IL (1) | IL177055A0 (pt) |
| NO (1) | NO20063842L (pt) |
| RU (1) | RU2006131043A (pt) |
| WO (1) | WO2005074904A2 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2521811A1 (en) | 2003-09-18 | 2005-03-31 | Axys Pharmaceuticals, Inc. | Haloalkyl containing compounds as cysteine protease inhibitors |
| WO2006060810A1 (en) | 2004-12-02 | 2006-06-08 | Schering Aktiengesellschaft | Sulfonamide compounds as cysteine protease inhibitors |
| PL1865940T3 (pl) | 2005-03-21 | 2013-06-28 | Virobay Inc | Alfa-ketoamidowe związki jako inhibitory proteaz cysteinowych |
| JP5215167B2 (ja) | 2005-03-22 | 2013-06-19 | ビロベイ，インコーポレイティド | システインプロテアーゼ阻害剤としてのスルホニル基含有化合物 |
| DK2079683T3 (en) | 2006-10-04 | 2015-04-27 | Virobay Inc | Difluoro-containing compounds as cysteine protease inhibitors |
| US7893112B2 (en) | 2006-10-04 | 2011-02-22 | Virobay, Inc. | Di-fluoro containing compounds as cysteine protease inhibitors |
| WO2008104271A2 (en) | 2007-02-28 | 2008-09-04 | Sanofi-Aventis | Imaging probes |
| US8324417B2 (en) | 2009-08-19 | 2012-12-04 | Virobay, Inc. | Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof |
| CN107922315B (zh) | 2015-08-29 | 2021-03-26 | 广东东阳光药业有限公司 | 组织蛋白酶k抑制剂及其用途 |
| JP7179721B2 (ja) | 2016-06-21 | 2022-11-29 | オリオン・オフサルモロジー・エルエルシー | 複素環式プロリンアミド誘導体 |
| JP7164521B2 (ja) | 2016-06-21 | 2022-11-01 | オリオン・オフサルモロジー・エルエルシー | 炭素環式プロリンアミド誘導体 |
| AU2020250933A1 (en) | 2019-04-05 | 2021-10-28 | Centre Hospitalier Régional Et Universitaire De Brest | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2251714A1 (en) * | 1996-04-22 | 1997-10-30 | Massachusetts Institute Of Technology | Suppression of immune response via inhibition of cathepsin s |
| TW200404789A (en) * | 1999-03-15 | 2004-04-01 | Axys Pharm Inc | Novel compounds and compositions as protease inhibitors |
| EP1516877A1 (en) * | 1999-03-15 | 2005-03-23 | Axys Pharmaceuticals, Inc. | Amine derivatives as protease inhibitors |
| US7101880B2 (en) * | 2002-06-24 | 2006-09-05 | Schering Aktiengesellschaft | Peptidic compounds as cysteine protease inhibitors |
| CA2521811A1 (en) * | 2003-09-18 | 2005-03-31 | Axys Pharmaceuticals, Inc. | Haloalkyl containing compounds as cysteine protease inhibitors |
-
2005
- 2005-01-31 RU RU2006131043/04A patent/RU2006131043A/ru unknown
- 2005-01-31 CA CA002554626A patent/CA2554626A1/en not_active Abandoned
- 2005-01-31 KR KR1020067017471A patent/KR20060129416A/ko not_active Withdrawn
- 2005-01-31 JP JP2006551515A patent/JP2007519744A/ja active Pending
- 2005-01-31 US US10/587,867 patent/US20070088001A1/en not_active Abandoned
- 2005-01-31 BR BRPI0506494-5A patent/BRPI0506494A/pt not_active Application Discontinuation
- 2005-01-31 AU AU2005210631A patent/AU2005210631A1/en not_active Abandoned
- 2005-01-31 WO PCT/US2005/002773 patent/WO2005074904A2/en not_active Ceased
- 2005-01-31 EP EP05722609A patent/EP1716158A2/en not_active Withdrawn
-
2006
- 2006-07-25 IL IL177055A patent/IL177055A0/en unknown
- 2006-08-28 CR CR8574A patent/CR8574A/es not_active Application Discontinuation
- 2006-08-29 NO NO20063842A patent/NO20063842L/no not_active Application Discontinuation
- 2006-08-29 EC EC2006006805A patent/ECSP066805A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005074904A3 (en) | 2005-09-29 |
| EP1716158A2 (en) | 2006-11-02 |
| JP2007519744A (ja) | 2007-07-19 |
| CA2554626A1 (en) | 2005-08-18 |
| ECSP066805A (es) | 2006-11-16 |
| IL177055A0 (en) | 2006-12-10 |
| US20070088001A1 (en) | 2007-04-19 |
| KR20060129416A (ko) | 2006-12-15 |
| AU2005210631A1 (en) | 2005-08-18 |
| WO2005074904A2 (en) | 2005-08-18 |
| BRPI0506494A (pt) | 2007-02-13 |
| CR8574A (es) | 2007-02-05 |
| RU2006131043A (ru) | 2008-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20061627L (no) | Haloalkyl inneholdende forbindelser som cysteinproteaseinhibitorer | |
| NO20075370L (no) | Alfa-ketoamidforbindelser som cysteinproteaseinhibitorer | |
| NO20084256L (no) | DPP IV inhibitorformuleringer | |
| NO20083202L (no) | ANG2- og VEFG-inhibitorkombinasjoner | |
| NO20040021L (no) | Beta-amino-tetrahydroimidaz(1,2-a)pyraziner og tetrahydrotriazolo(4,3-a)pyraziner, farmasøytiske preparater som omfatter forbindelsene, og anvendelse av forbindelsene ved fremstilling av medikamenter for anvendelse ved behandling av sukkersyke type II. | |
| WO2008033562A3 (en) | Kinase inhibitor compounds | |
| GEP20135724B (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes | |
| NO20055863L (no) | W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer | |
| NO20065847L (no) | Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase | |
| MX2009006327A (es) | Compuestos heterociclicos y metodos de uso de los mismos. | |
| NO20064584L (no) | Tetrahydropyridoindolderivater | |
| UA100111C2 (ru) | Лечение диабета типа 2 комбинацией ингибитора dpiv и метформина или тиазолидиндиона | |
| NO20073631L (no) | Metasubstituerte tiazolidinoner, fremgangsmate for fremstilling og anvendelse av disse som legemiddel | |
| MX2009010205A (es) | Inhibidores de cetoamida p1-no epimerizables de proteasa ns3 de virus de hepatitis c. | |
| CY1107342T1 (el) | Χρηση παραγωγων νιτριλιου ως φαρμακο | |
| WO2005074904A3 (en) | Silinane compounds as cysteine protease inhibitors | |
| WO2006078576A3 (en) | Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease | |
| TW200716091A (en) | New therapeutic combinations for the treatment or prevention of psychotic disorders | |
| WO2005063742A3 (en) | Amidino compounds as cysteine protease inhibitors | |
| DE60313803D1 (de) | Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen | |
| MX2009003563A (es) | Compuestos que contienen di-fluoro como inhibidores de proteasa de cisteina. | |
| NO20084190L (no) | Anvendelse av VX-702 til behandling av revmatoid artritt | |
| IL189286A0 (en) | Novel cysteine protease inhibitors and their therapeutic applications | |
| MX2007011739A (es) | Compuestos que contienen sulfonilo como inhibidores de cisteina proteasa. | |
| WO2010056877A3 (en) | Haloalkyl containing compounds as cysteine protease inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |